{"url_path":"/sec/pdsb/8-k/2026-05-13/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operation and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-020934-index.html","accession_number":"0001140361-26-020934","cik":"0001472091","ticker":"PDSB","issuer_name":"PDS Biotechnology Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1472091/0001140361-26-020934-index.html","primary_entity_key":"0001472091","primary_entity_name":"PDS Biotechnology Corp"},"word_count":156,"has_tables":true,"body_markdown":"Item 2.02\n\nResults of Operation and Financial Condition.\n\nOn May 13, 2026, PDS Biotechnology Corporation (the “Company”) issued a press release announcing a business update and its\nfinancial results for the quarter ended March 31, 2026. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.\n\nIn accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including\nExhibit 99.1) is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of the section, nor\nshall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing."}